Jerini’s Icatibant Could Be Second To Market For Hereditary Angioedema
This article was originally published in The Pink Sheet Daily
Executive Summary
Jerini submits NDA for bradykinin blocker just over two months after Lev Pharmaceuticals’ Cinryze was filed.